Drug intelligence / Profile preview

CCT-101

Development stage: Preclinical
Lead developer: Cell Care Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

CCT-101 is an investigational exosome-based therapy developed by Cell Care Therapeutics. It is being researched primarily for the treatment of diabetic macular oedema, with additional potential applications in cardiovascular diseases, endocrinology and metabolic diseases, and eye diseases. As an exosome therapy, CCT-101 likely leverages the natural intercellular communication properties of exosomes to deliver therapeutic effects; however, specific details about its mechanism of action or molecular targets have not been disclosed publicly. The drug remains in preclinical development as of May 2025[2].

Beyond the preview

Go deeper on CCT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCT-101.

Explore the full profile